Eargo is a potential significant disruptor in overpriced hearing aid devices, an industry that has not reinvented itself for a long time. Hearing loss is currently the third largest medical condition in the US, with an estimated 44M people affected. Eargo’s devices cater to mild and moderate hearing loss, representing the vast majority of those affected at over than 38M. The presentation walks through differentiating points of technology, prices vs traditional aids and long term growth opportunity. When you watch this video, consider how Align Tech (ALGN) disrupted dental space with Invisalign, and Dexcom (DXCM) disrupted diabetes testing with CGM. Better tech, better results, lower price. Both of those stocks went up 10x over the years. The same applies to Eargo in hearing aid business. Full research note and slide deck attached on website.

 

 

Attachments: Slide Deck | Research Note